Biocodex
Description
Biocodex is a French 100% family-owned business, founded in 1953 and headquartered in Paris area. The initial focus of the company was gastro-enterology, featuring a unique probiotic: Saccharomyces Boulardii CNCM I-745®, the first probiotic drug to have a positive effect on intestinal microbiota. Since then, Biocodex has evolved from a pioneer to an international key player in the microbiota realm and has diversified. In 2020, Biocodex completed the acquisition of Laboratoires IPRAD, the French leader on the women’s health segment.
Biocodex employs 1 700 people, completed 567M€ Net Turnover in 2023 and is present in more than countries, out of which 16 countries through its owned subsidiaries.
Our mission at Biocodex is to improve the health and well-being of women and men worldwide through our three main areas of expertise: microbiota, women’s health and orphan diseases.
Company members
Aurore Matton
